AbbVie: Leukemia trials
The registry lists 11 Leukemia studies with AbbVie as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 3Phase 2 6Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT03342144
- A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaCompletedNCT03873493Phase 2Results posted
- A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyCompletedNCT03069352Phase 3Results posted
- Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2Results posted
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
- A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaActive, not recruitingNCT02966756Phase 2
- A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
- A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedNCT01149668Phase 1
- Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00290004Phase 1/2
- Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00100711Phase 2
- A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00076401Phase 2